GlassScriptPhysician profile
Joseph Micci, III
NPI 1538704465
$3,098.10
in general payments reported to CMS, 2019-2025
18 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $651 · 2022: $1,130 · 2023: $471 · 2024: $341 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202 · Consulting Fee: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.51 |
| Consulting Fee | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $670.93 | 2021-2025 | Caplyta |
| Abbvie INC. | $506.99 | 2021-2024 | |
| Alkermes, INC. | $411.39 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Lundbeck LLC | $276.65 | 2021-2025 | Rexulti |
| Indivior INC. | $198.87 | 2021-2025 | Sublocade |
| Neurocrine Biosciences, INC. | $180.22 | 2022-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $170.88 | 2021-2025 | Rexulti |
| Janssen Scientific Affairs, LLC | $115.00 | 2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $106.32 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.37 | 2022-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $83.17 | 2022-2025 | Spravato |
| Braeburn INC. | $66.68 | 2023-2024 | Brixadi |
| Axsome Therapeutics, INC. | $59.64 | 2022-2025 | Auvelity |
| Orexo US, INC. | $47.13 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $34.42 | 2025 | Cobenfy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $32.03 | 2023 | Qelbree |
| Merck Sharp & Dohme LLC | $30.41 | 2021-2022 | |
| Eisai INC. | $20.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Micci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.